New Class of Drugs Might Change the Landscape for Migraine Treatment
University of KentuckyCGRP monoclonal antibodies appear to significantly reduce the frequency of migraine in human clinical trials, potentially changing the landscape for migraine treatment. Headache specialist Sid Kapoor, MD, discusses the enormous potential -- and pitfalls-- facing the drug class' road to FDA approval.